Business Wire

1E

1.10.2020 13:16:05 CEST | Business Wire | Press release

Share
IT Departments that aren’t Listening to Employees Will Fail in 2021, says 1E

Endpoint automation leader 1E has announced new features to their market leading digital experience management offering, Tachyon Experience, helping enterprises truly understand how users experience their IT.

Sentiment as a leading indicator in a Remote First World

In a remote first world, knowledge workers increasingly rely on their endpoint to be performant and responsive; The endpoint is their entire conduit to the workplace. Recent research by Vanson Bourne showed that the overwhelming majority (98%) of remote workers found endpoint performance to be important, yet more than half (53%) saying that their machine runs more slowly outside the office. IT has historically lacked the tools to identify and remediate these issues. Tachyon Experience has been built to provide IT analytics of the aggregated digital experience of users across the entire endpoint estate down to the sentiment of an individual user.

“Almost every knowledge worker is working remotely, but they have an inferior experience to working in the office. Businesses that succeed in a remote first world will provide a first class digital experience to all employees wherever they are. IT departments need tools which monitor digital experience, gather employee sentiment and remediate issues as they happen.” said Sumir Karayi, CEO and Founder, 1E

Tachyon Sentiment joining up previously siloed datasets

Integration is where Tachyon Sentiment differentiates over the traditional survey approach; Traditionally, IT departments have conducted periodic NPS polls, but this has rarely been joined up to the applications and device they’re using. This siloed approach to data clouds any real digital experience insights. For the first time, IT departments are able to correlate a user’s sentiment or perception of IT with actual telemetry from the endpoint that they’re using. Tachyon Experience aggregates end user sentiment with endpoint metrics (stability, performance and responsiveness) into a single, overarching Digital Experience score.

“Sentiment is a vital expansion to our Tachyon Experience offering as it allows IT departments the ability to identify users that appear to be having a solid experience from a technical metrics perspective, but in reality, are having a frustrating time with some of their applications or day to day end point experience”, says Rob Peterscheck, VP of Product for 1E

The new Sentiment capability in 1E Tachyon Experience introduces unparalleled flexibility and integration in comparison to traditional approaches to gathering user feedback. Users can be polled on an ad-hoc basis, scheduled or in response to a specific event (for example an IT change or upgrade). “The ability to collect user feedback in real time in response to major transformation initiatives or rollouts will also be a major asset to IT operations teams who have previously used trailing indicators such as escalation of service desk tickets” said Peterscheck.

Digital Experience, not just the purview of the IT department

The addition of Sentiment to Tachyon Experience marks a vital step in a market shift to broaden the appeal of Digital Experience Monitoring tools beyond the IT department. “Given the challenges of remote working for employees and the tighter relationship between HR and IT, we see the Tachyon Experience playing a part in further desiloing data and toolsets between our departments. HR routinely ask employees how they feel about their workplace using traditional tools, but in this new world, the laptop is their workplace and hence it makes sense to share the data between the departments” said Nick Bartlett, Chief People Officer for 1E

For more information on 1E Tachyon Experience, attend the launch webinar on 15th of October at https://info.1e.com/tachyon-sentiment-launch or visit www.1E.com .

Statistics referenced throughout are taken from 1E’s latest research ‘The new digital workplace: employee experiences with universal remote working since COVID’. You can read the full research here: www.1E.com/wfa-research

####

About 1E

1E offers the only real-time remote endpoint automation solution that helps IT actively manage employee experience in real-time. Giving IT teams total control and visibility over all remote endpoints, Tachyon offers in-depth analytics to understand and improve the experience employees have with their endpoints. It delivers

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release

New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release

By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release

Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye